Alcyomics Limited
Other human health activities · Newcastle Upon Tyne
ActiveUnited KingdomIncorporated 2007Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2026-02-28
IXBRL · 159 source facts · 24 selected values
Validation findingsXBRL valid
Accounts to 2026-02-28
IXBRL · 159 source facts · 24 selected values
Validation findings
XBRL valid
- Reporting period
- 2025-03-01 to 2026-02-28
- Extraction status
- complete
- Numeric facts
- 94
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2025-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod223_4307_06102853_20260228
- Source archive
- Accounts_Bulk_Data-2026-09-15.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2025-02-28
IXBRL · 147 source facts · 24 selected values
Validation findingsXBRL valid
Accounts to 2025-02-28
IXBRL · 147 source facts · 24 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-03-01 to 2025-02-28
- Extraction status
- complete
- Numeric facts
- 83
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2510_06102853_20250228
- Source archive
- Accounts_Monthly_Data-October2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2024-02-29
IXBRL · 146 source facts · 24 selected values
Not assessedlegacy record
Accounts to 2024-02-29
IXBRL · 146 source facts · 24 selected values
Not assessed
legacy record
- Reporting period
- 2023-03-01 to 2024-02-29
- Extraction status
- Legacy / not assessed
- Numeric facts
- 83
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2022-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_3100_06102853_20240229
- Source archive
- Accounts_Monthly_Data-November2024.zip
Accounts to 2023-02-28
IXBRL · 141 source facts · 0 selected values
Not assessedlegacy record
Accounts to 2023-02-28
IXBRL · 141 source facts · 0 selected values
Not assessed
legacy record
- Reporting period
- 2022-03-01 to 2023-02-28
- Extraction status
- Legacy / not assessed
- Numeric facts
- 77
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2022-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0033_06102853_20230228
- Source archive
- Accounts_Monthly_Data-November2023.zip
Accounts to 2022-02-28
IXBRL · 147 source facts · 26 selected values
Not assessedlegacy record
Accounts to 2022-02-28
IXBRL · 147 source facts · 26 selected values
Not assessed
legacy record
- Reporting period
- 2021-03-01 to 2022-02-28
- Extraction status
- Legacy / not assessed
- Numeric facts
- 82
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- secr-frs-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0107_06102853_20220228
- Source archive
- Accounts_Monthly_Data-June2022.zip
Accounts to 2018-02-28
IXBRL · 121 source facts · 21 selected values
Not assessedlegacy record
Accounts to 2018-02-28
IXBRL · 121 source facts · 21 selected values
Not assessed
legacy record
- Reporting period
- 2017-03-01 to 2018-02-28
- Extraction status
- Legacy / not assessed
- Numeric facts
- 59
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0060_06102853_20180228
- Source archive
- Accounts_Monthly_Data-November2018.zip
Registered details
06102853- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2007-02-14
- Jurisdiction
- —
- Registered office
- THE BIOSPHERE, DRAYMANS WAY, NEWCASTLE UPON TYNE, NE4 5BX, ENGLAND
Classification
1 SIC codes86900
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
24 matched grantsEvaluation of novel therapeutics for the treatment of severe skin blistering adverse drug reactionsActiveMRC · Studentship · 2024-09-30 – 2028-09-29 · with 1 other participant£0whole project
Evaluation of novel therapeutics for the treatment of severe skin blistering adverse drug reactionsActive
MRC · Studentship · 2024-09-30 – 2028-09-29 · with 1 other participant
£0
whole project
University of LiverpoolleadAlcyomics Ltd
Stop GvhdLead
Innovate UK · EU-Funded · 2023-11-01 – 2025-04-30
£193,015
awarded
Stop Gvhd
EU · EU-Funded · 2023-11-01 – 2025-04-29
£193,015
whole project
Stop GvhdLead
EU · EU-Funded · 2023-11-01 – 2025-04-29
£193,015
whole project
Development of an innervated in vitro Osteoarthritis Model for Drug Discovery and Drug ScreeningLead
Innovate UK · Collaborative R&D · 2023-01-01 – 2023-12-31
£339,502
awarded
Further Development, Validation and Commercialisation of an Osteoarthritis Model for Drug Discovery and Drug Screening.Lead
Innovate UK · Investment Accelerator · 2022-08-01 – 2023-04-30
£0
awarded
Use of 3D skin models and patient-derived immune cells to elucidate the molecular mechanisms of skin detachment in severe drug-induced skin adverse reMRC · Studentship · 2021-09-30 – 2023-09-29 · with 1 other participant£0whole project
Use of 3D skin models and patient-derived immune cells to elucidate the molecular mechanisms of skin detachment in severe drug-induced skin adverse re
MRC · Studentship · 2021-09-30 – 2023-09-29 · with 1 other participant
£0
whole project
University of LiverpoolleadAlcyomics Ltd
Further Development and Innervation of a 96 Well, 3D, Skin Model for Drug and Toxicity TestingLead
Innovate UK · Innovation Loans · 2021-04-08 – 2022-10-08
£350,000
awarded
Northern Alliance ATTCInnovate UK · Centres · 2021-04-01 – 2022-03-31 · with 20 other participants£122,284awarded
Northern Alliance ATTC
Innovate UK · Centres · 2021-04-01 – 2022-03-31 · with 20 other participants
£122,284
awarded
The Newcastle upon Tyne Hospitals NHS Foundation Trustlead£566,226
Leeds Teaching Hospitals NHS Trust£301,910
University of Edinburgh£232,927
Scottish National Blood Transfusion Service£148,496
Greater Glasgow Health Board£145,285
Alcyomics Limited£122,284
NHS Blood and Transplant£14,274
NHS Lothian£3,553
Sheffield Teaching Hospitals NHS Foundation Trust£0
University of Glasgow£0
Northern Alliance ATTCISCF · Centres · 2021-03-31 – 2022-03-30 · with 20 other participants£2,080,814whole project
Northern Alliance ATTC
ISCF · Centres · 2021-03-31 – 2022-03-30 · with 20 other participants
£2,080,814
whole project
The Newcastle Upon Tyne Hospitals NHS Foundation TrustleadAchilles Therapeutics UK LimitedAlcyomics LimitedAutolus LimitedDatatrial LimitedGlobal Life Sciences Solutions Operations UK LtdGreater Glasgow Health BoardHealth Innovation North East And North Cumbria LimitedLeeds Teaching Hospitals NHS TrustNewcastle UniversityNHS Blood And TransplantNHS LothianPhion Therapeutics LtdScottish National Blood Transfusion ServiceSheffield Teaching Hospitals NHS Foundation TrustThermo Electron LimitedTrakcel LimitedUniversity Of EdinburghUniversity Of GlasgowVascversa LtdWorld Courier Management Limited
Immune response to COVID-19 ;Predicting SusceptibilityLead
Innovate UK · Feasibility Studies · 2020-06-01 – 2021-03-31
£75,000
awarded
Northern Alliance Advanced Therapies Treatment CentreISCF · Collaborative R&D · 2018-03-01 – 2022-03-30 · with 19 other participants£7,544,329whole project
Northern Alliance Advanced Therapies Treatment Centre
ISCF · Collaborative R&D · 2018-03-01 – 2022-03-30 · with 19 other participants
£7,544,329
whole project
The Newcastle Upon Tyne Hospitals NHS Foundation TrustleadAlcyomics LimitedAsymptote LimitedAutolus LimitedCell Medica LimitedChiesi LimitedDatatrial LimitedHealth Innovation North East And North Cumbria LimitedLothian Health BoardMiltenyi Biotec LimitedNewcastle UniversityNHS Blood And TransplantNHS Greater Glasgow And ClydeRoslin Cell Therapies LimitedScottish National Blood Transfusion ServiceThe Leeds Teaching Hospitals NHS TrustThermo Electron LimitedTrakcel LimitedUniversity Of EdinburghWorld Courier Logistics (UK) Limited
Northern Alliance Advanced Therapies Treatment CentreInnovate UK · Collaborative R&D · 2018-03-01 – 2022-03-31 · with 19 other participants£212,574awarded
Northern Alliance Advanced Therapies Treatment Centre
Innovate UK · Collaborative R&D · 2018-03-01 – 2022-03-31 · with 19 other participants
£212,574
awarded
The Newcastle upon Tyne Hospitals NHS Foundation Trustlead£1,623,506
Newcastle University£701,226
Scottish National Blood Transfusion Service£470,116
The Leeds Teaching Hospitals NHS Trust£459,749
Lothian Health Board£308,221
University of Edinburgh£276,428
NHS Blood and Transplant£261,849
NHS Greater Glasgow and Clyde£227,470
Alcyomics Limited£212,574
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testingLeadInnovate UK · Collaborative R&D · 2017-08-01 – 2019-07-31 · with 1 other participant£144,196awarded
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testingLead
Innovate UK · Collaborative R&D · 2017-08-01 – 2019-07-31 · with 1 other participant
£144,196
awarded
Alcyomics Limitedlead£144,196
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testingISCF · Collaborative R&D · 2017-07-31 – 2019-07-30 · with 1 other participant£203,945whole project
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testing
ISCF · Collaborative R&D · 2017-07-31 – 2019-07-30 · with 1 other participant
£203,945
whole project
Alcyomics LimitedleadReprocell Europe Limited
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testingLeadISCF · Collaborative R&D · 2017-07-31 – 2019-07-30 · with 1 other participant£203,945whole project
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testingLead
ISCF · Collaborative R&D · 2017-07-31 – 2019-07-30 · with 1 other participant
£203,945
whole project
Alcyomics LimitedleadReprocell Europe Limited
Alcyomics Ltd (add on to 102265)Lead
Innovate UK · SME Support · 2015-10-01 – 2015-12-31
£1,500
awarded
Improving manufacture and commercialisation of a 3D skin model for drug safetyLead
Innovate UK · Launchpad · 2015-08-01 – 2017-04-30
£117,566
awarded
Newcastle University and Alcyomics LimitedInnovate UK · Knowledge Transfer Partnership · 2014-09-01 – 2015-07-31 · with 1 other participant
Newcastle University and Alcyomics Limited
Innovate UK · Knowledge Transfer Partnership · 2014-09-01 – 2015-07-31 · with 1 other participant
University of Newcastlelead£45,476
Alcyomics Limited—
Nuq®Lead
Innovate UK · EU-Funded · 2013-12-01 – 2016-05-31
£107,372
awarded
NuQ®Lead
EU · EU-Funded · 2013-12-01 – 2016-05-30
£107,372
whole project
NuQ®
EU · EU-Funded · 2013-12-01 – 2016-05-30
£107,372
whole project
'In Vitro human skin testing; safety, allergy and contact sensitivity'Lead
Innovate UK · GRD Development of Prototype · 2012-03-01 – 2013-05-31
£53,658
awarded
Development of a skin explant assay as a unique tool for the biotechnology and pharmaceutical industryLead
Innovate UK · Legacy RDA Grant for R&D · 2010-05-01 – 2011-10-31
£100,000
awarded
University stake evidence
Newcastle University Holdings Limited
psc · 25-50% band